Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.
Indication: Used in the treatment of local infections; mainly infections of the mouth, throat and superficial skin wounds.
Application: Formulated alone or in combination drug products used in lozenges and topicals.
Presentations |
|
||||||||||||||||||
Product grades |
Non-sterile | ||||||||||||||||||
Compliance |
Ph. Eur. USP |
||||||||||||||||||
Manufacturing site |
Xellia Pharmaceuticals Ltd., Budapest, Hungary |
||||||||||||||||||
Release site |
Xellia Pharmaceuticals Ltd., Budapest, Hungary |
||||||||||||||||||
Site registered |
EU GMP issued by Hungarian National Institute of Pharmacy recognised by FDA from March 1st 2018 according to Mutual Recognition Agreement (MRA) |
||||||||||||||||||
Regulatory documentation |
EU Drug Master File (DMF) Certificate of Suitability (CEP) |
||||||||||||||||||
Packaging sizes |
|
||||||||||||||||||
Packaging material |
|
||||||||||||||||||
Shelf life |
| ||||||||||||||||||
Storage conditions |
| ||||||||||||||||||
